AMGEN OBESITY GENE WEIGHS IN FAVORABLY IN JULY, STOCK GAINS 4-3/4 POINTS; BIOTECH BOOMS IN MONTH, WITH "F-D-C" INDEX PHARMACEUTICAL COMPONENT GAINING 9.5%
The enthusiastic reception by investors of Amgen's preclinical work on the obesity gene is evidence that the luster is back on biotechnology